Skip to content
Peptide research

Argireline

Also known as Acetyl Hexapeptide-8
Category
Skin & Cosmetic
Administration routes
Topical
Regulatory status
Cosmetic ingredient

A synthetic hexapeptide sold in cosmetic serums as a needle-free alternative to botulinum toxin for crow's feet and expression lines. Human evidence for modest wrinkle reduction is moderate and tolerability looks favorable, but efficacy is inconsistent, skin penetration is doubtful given the peptide's size, and claims it rivals botox are speculative. It is a cosmetic ingredient, not an approved drug, carries no FDA approval, and purity varies among products.

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.

Overview

Argireline (acetyl hexapeptide-8) is a synthetic six-amino-acid peptide marketed as a topical alternative to Botox for reducing expression lines and wrinkles. Developed by Lipotec (now Lubrizol) in 2001, it works by gently interfering with the same neuromuscular signaling that Botox targets — but in a milder, reversible way that does not require injection. It is one of the most widely used cosmetic peptides in anti-aging skincare products worldwide.

How it works in the body

Competes with a protein called SNAP-25 that is needed for nerve signals to reach facial muscles. By partially blocking this nerve-to-muscle communication, it reduces the intensity of muscle contractions that create expression lines — similar to botulinum toxin but much milder.

Research overview

Argireline works by competing with a protein called SNAP-25, which is part of the machinery that allows nerve signals to trigger muscle contractions. By interfering with this process, it mildly relaxes the facial muscles responsible for expression wrinkles — similar in concept to Botox but much gentler and fully reversible. Clinical evidence is mixed: an early study showed up to 30% wrinkle depth reduction after 30 days of a 10% topical solution, and a randomized controlled trial reported a nearly 49% subjective response rate versus 0% for placebo. However, a more rigorous 2023 study using objective imaging found no statistically significant difference between Argireline-containing serum and the same serum without Argireline. A key limitation is that less than 0.2% of the peptide actually penetrates the outer skin layer within 24 hours, raising questions about whether enough reaches the target muscles to be effective. No serious side effects were reported across the studies.

Who researches Argireline?

Commonly researched by

  • People researching skin health and rejuvenation

    Studied for collagen synthesis, skin repair, or anti-aging skin effects.

  • People researching longevity and anti-aging interventions

    Studied for effects on aging pathways, cellular health, or lifespan extension.

Important considerations for

  • Those who are pregnant or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Anyone under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Those with Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

Safety & interactions

General cautions

  • Pregnancy or breastfeeding

    Absolute

    No human reproductive safety data exists for this peptide. Effects on fetal development are unknown.

  • Children under 18

    Absolute

    No pediatric safety data. Not recommended for use in minors.

  • Known hypersensitivity

    Absolute

    Discontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).

How to read the ratings

Benefits
= confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Risks
= level of concern: High · Moderate · Low · Theoretical
Interactions
= direction with this peptide: Protective / Synergistic · Caution · Neutral

Risk summary(5)

Rated by level of concern

  • Minimal skin penetration

    High

    PMID 24754410 (Kraeling et al., Cutan Ocul Toxicol 2015;34(1):46-52, DOI 10.3109/15569527.2014.894521); Mortazavi & Moghimi, Int J Cosmet Sci 2022;44(2), DOI 10.1111/ics.12770; PMC12193160

  • Mild local irritation

    Low

    PMID 23146065 (Eur J Neurol 2013); PMID 23417317; CIR draft Safety Assessment (cir-safety.org), irritation/ocular sections

  • Injection-related adverse events

    Moderate

    PMID 33748252 (World J Clin Cases 2021, DOI 10.12998/wjcc.v9.i8.1996); PMC11801139 (Int J Womens Dermatol 2022, systematic review of mesotherapy-associated NTM infections - mesotherapy in general, not argireline-specific)

  • Inconsistent clinical efficacy

    High

    PMC12193160 (Int J Mol Sci 2025;26(12):5722); PMID 23417317; PMID 33911590 (Ann Dermatol 2019;31(3):263-71); DOI 10.1111/ics.12770

  • Potential for exaggerated marketing claims

    High

    PMC12193160 (Int J Mol Sci 2025;26(12):5722); PMID 38376906 (JMIR Dermatol 2024)

Interaction summary(7)

Rated by direction with this peptide

  • Botulinum toxin type A (onabotulinumtoxinA and related)

    SynergisticLow

    Both act at the SNARE complex (argireline competes with SNAP-25, BoNT cleaves it), and a small double-blind placebo-controlled pilot in 24 blepharospasm patients found a trend toward longer duration of BoNT effect (3.7 vs 3.0 months) with topical 0.005% acetyl hexapeptide-8, with no severe adverse events. The difference was not statistically significant, the trial was underpowered, and it has not been replicated - so any additive effect is suggestive at best, and there is no evidence of harm from co-use.

    PMID 23146065 (Eur J Neurol 2013, DOI 10.1111/ene.12009); ClinicalTrials.gov NCT00942851

  • Physical penetration enhancers (microneedling, iontophoresis, fractional laser, microneedle patches)

    SynergisticLow

    Barrier disruption is the main proposed route to meaningful delivery, since passive flux of this hydrophilic ~889 Da peptide is negligible; permeability reviews argue enhancement is a prerequisite for performance, and a randomized split-face trial delivered acetyl hexapeptide-8 in a cross-linked hyaluronic acid microneedle patch. Note that in that trial the vehicle-only patch also improved wrinkles significantly, so enhanced delivery is not proven to translate into added peptide benefit - while it does plausibly raise local irritation and, with skin puncture, infection risk.

    DOI 10.1111/ics.12770 (Mortazavi & Moghimi, Int J Cosmet Sci 2022); PMID 33911590 (An et al., Ann Dermatol 2019;31(3):263-71); PMC12193160

  • Topical retinoids, alpha/beta hydroxy acids and other barrier-disrupting actives

    CautionLow

    Compromising the stratum corneum increases peptide uptake but also adds irritant potential; the practical consequence is additive erythema and stinging rather than any systemic hazard. No direct interaction study exists; this is mechanism-based inference from the penetration literature.

    Mechanistic inference from penetration data: PMID 24754410 (Kraeling et al., Cutan Ocul Toxicol 2015); DOI 10.1111/ics.12770

  • Mesotherapy / intradermal injection procedures (non-sterile or unapproved compounding)

    CautionModerate

    Injecting argireline is an unapproved route with no safety assessment behind it, and a documented case of Mycobacterium abscessus facial abscesses and granulomatous nodules followed intradermal argireline injection, consistent with the wider mesotherapy literature on non-tuberculous mycobacterial infection (423 patients across 30 studies, frequently traced to contaminated injectate).

    PMID 33748252 (World J Clin Cases 2021, DOI 10.12998/wjcc.v9.i8.1996); PMC11801139 (Int J Womens Dermatol 2022)

  • Aminoglycoside antibiotics and neuromuscular blocking agents

    NeutralTheoretical

    These agents impair neuromuscular transmission and would in principle compound any SNARE-level inhibition, but topical argireline delivers essentially nothing past the stratum corneum (none detected in dermis or receptor fluid at 24 h in FDA in vitro work), no clinical interaction has ever been reported, and none is expected. Listed for completeness rather than as an actionable caution.

    Mechanistic; penetration data from PMID 24754410 (Kraeling et al., Cutan Ocul Toxicol 2015, DOI 10.3109/15569527.2014.894521)

  • Pre-existing neuromuscular disease therapy (myasthenia gravis, Lambert-Eaton; e.g., pyridostigmine)

    CautionTheoretical

    A SNAP-25 competitor is theoretically undesirable in disorders of neuromuscular transmission, and labeling for injectable SNARE-targeting agents warns that patients with these conditions may be at increased risk of systemic effects. No case of clinical worsening from topical acetyl hexapeptide-8 has been published and systemic exposure appears negligible, so this is a precautionary class analogy only.

    Mechanistic; class-analogy to botulinum toxin labeling (FDA BOTOX prescribing information, warning for patients with neuromuscular disorders)

  • Systemic medications (oral drugs, CYP substrates)

    NeutralLow

    No meaningful systemic absorption has been demonstrated from topical use - in FDA in vitro studies the peptide was confined largely to the stratum corneum, with ~0.01% of applied dose in the epidermis and none detected in dermis or receptor phase - so pharmacokinetic drug interactions are not expected.

    PMID 24754410 (Kraeling et al., Cutan Ocul Toxicol 2015, DOI 10.3109/15569527.2014.894521)

Known risks(5)

  • Minimal skin penetration

    Efficacy limitation

    Less than 0.2% of topically applied Argireline penetrates the stratum corneum within 24 hours, raising questions about whether therapeutically relevant concentrations reach neuromuscular targets in deeper skin layers.

  • Mild local irritation

    Low

    Occasional mild tingling, stinging upon application, and rare reports of redness or dry/flaky skin at contact points. More common on sunburned or irritated skin.

  • Injection-related adverse events

    Low (only with misuse)

    Rare reports of adverse effects are predominantly associated with practices deviating from normal cosmetic use, notably injections. Argireline is intended for topical use only.

  • Inconsistent clinical efficacy

    Efficacy limitation

    Clinical evidence is mixed. The most rigorous study (Henseler 2023, using objective Visia imaging) found no statistically significant wrinkle reduction attributable to Argireline. Earlier positive studies also included objective skin-replica measurements.

  • Potential for exaggerated marketing claims

    Consumer awareness

    Often marketed as "Botox in a bottle" despite having far lower efficacy than botulinum toxin. Consumers may have unrealistic expectations.

Drug interactions(3)

  • Botulinum toxin (Botox, Dysport, Xeomin)

    Low risk — may be complementary

    Theoretically additive effect since both target the SNARE complex. A pilot study (Lungu et al. 2012) used topical Argireline as an adjunct to botulinum toxin therapy without adverse interactions, showing potential for extended inter-injection intervals.

  • Other topical cosmetic actives (retinoids, AHAs, BHAs)

    Minimal

    No known adverse interactions. Commonly formulated alongside hyaluronic acid, niacinamide, and other cosmetic peptides. May apply to compromised skin barrier from strong actives, potentially increasing local irritation.

  • No systemic drug interactions identified

    Due to extremely low skin penetration (<0.2% in 24 hours) and topical-only route of administration, systemic drug interactions are not expected. No formal drug interaction studies have been conducted.

Research & benefits

Evidence base

Evidence Level
Moderate
Total Studies
8
Human Studies
5

Clinical evidence for Argireline is mixed. Early studies used subjective ratings and objective skin-replica measurements. The 2013 RCT reported a 48.9% subjective response rate and improved objective roughness measures. However, a more recent study using objective Visia imaging found no statistically significant effect attributable to Argireline specifically (both sides received hyaluronic acid serum, and neither within-side improvement was statistically significant). The fundamental limitation is extremely poor skin penetration (<0.2% in 24 hours), which raises questions about whether bioactive concentrations reach neuromuscular targets. Safety evidence is consistently strong across all studies.

Researched for(5)

Rated by confidence in the evidence

  • Reduction of expression wrinkles (crow's feet, forehead lines, periorbital wrinkles)

    Medium

    A small human RCT showed significant wrinkle reduction versus placebo, but replication is lacking.

    PMID 23417317 (Wang et al., Am J Clin Dermatol 2013;14(2):147-53); PMID 33911590 (An et al., Ann Dermatol 2019;31(3):263-71); PMID 33151254 (Clin Ter 2020;171(6):e539-48, retrospective, n=26); review: PMC12193160 (Int J Mol Sci 2025;26(12):5722, DOI 10.3390/ijms26125722)

  • Non-invasive alternative to botulinum toxin injections

    Speculative

    No head-to-head human trials exist; topical form does not reach facial muscle tissue.

    PMC12193160 (Int J Mol Sci 2025;26(12):5722); PMID 24754410 (Kraeling et al., Cutan Ocul Toxicol 2015;34(1):46-52, DOI 10.3109/15569527.2014.894521)

  • Favorable safety and tolerability profile

    Medium

    Small human studies report good tolerability at low concentrations, with no serious adverse events.

    PMID 23146065 (Lungu et al., Eur J Neurol 2013, DOI 10.1111/ene.12009); PMID 23417317; CIR final assessment, April 2021: safe up to 0.005% actual peptide; insufficient data above that concentration (https://www.cir-safety.org/sites/default/files/acetyl032021FR.pdf)

  • Potential adjunct to botulinum toxin therapy (extended inter-injection intervals)

    Speculative

    One small pilot trial found only a non-significant trend toward longer effect duration.

    PMID 23146065 (Eur J Neurol 2013, DOI 10.1111/ene.12009); ClinicalTrials.gov NCT00942851

  • Accessible and affordable anti-aging treatment

    Low

    Widely sold over-the-counter, but affordability has not been linked to demonstrated efficacy.

    PMID 38376906 (JMIR Dermatol 2024, Google-trends longitudinal analysis); CIR draft Safety Assessment (cir-safety.org) for VCRP frequency and 2019 concentration-of-use survey data

Benefits(5)

  • Reduction of expression wrinkles (crow's feet, forehead lines, periorbital wrinkles)

    Blanes-Mira et al. 2002 (30% wrinkle depth reduction at 30 days); Wang et al. 2013 RCT (48.9% efficacy vs 0% placebo)

  • Non-invasive alternative to botulinum toxin injections

    Multiple studies confirm topical application is painless with no injection-related risks (ptosis, bruising)

  • Favorable safety and tolerability profile

    Grosicki et al. 2014 cytotoxicity study; CIR Safety Assessment; all clinical trials report no serious adverse events

  • Potential adjunct to botulinum toxin therapy (extended inter-injection intervals)

    Lungu et al. 2012 pilot RCT showed trend toward extended botulinum toxin effect duration (3.7 vs 3.0 months)

  • Accessible and affordable anti-aging treatment

    OTC products typically under $100 vs $300-600 for professional Botox injections (Olsson et al. 2024)

Key studies(6)

  1. A synthetic hexapeptide (Argireline) with antiwrinkle activity

    In vitro + in vivo pilot studySmall cohort of healthy women volunteers30 days

    Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernandez-Ballester G, Ponsati B, Gutierrez L, Perez-Paya E, Ferrer-Montiel A

    International Journal of Cosmetic Science

    2002

    Topical 10% Argireline in O/W emulsion reduced wrinkle depth up to 30% after 30 days. Mechanism confirmed as SNARE complex inhibition via SNAP-25 mimicry. No oral toxicity or primary irritation observed.

  2. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study

    Randomized, double-blind, placebo-controlled trial60 subjects (3:1 ratio argireline:placebo)4 weeks (twice-daily application)

    Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J

    American Journal of Clinical Dermatology

    2013

    Total anti-wrinkle efficacy was 48.9% in the Argireline group vs 0% in placebo. Roughness parameters significantly decreased (p<0.01) in treatment group with no change in placebo (p>0.05).

  3. Henseler H

    GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW

    2023

    No statistically significant wrinkle reduction attributable to Argireline. Wrinkle scores decreased nonsignificantly on both the Argireline-serum side (p=0.060) and vehicle-only serum side (p=0.176), with no significant difference between sides (p=0.829). Concluded Argireline is not an alternative to botulinum toxin.

  4. Pilot Study of Topical Acetyl Hexapeptide-8 in Treatment of Blepharospasm in Patients Receiving Botulinum Neurotoxin Therapy

    Double-blind, placebo-controlled, randomized controlled trial24 patients (12 active, 12 placebo)Until return to baseline symptom severity

    Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M

    European Journal of Neurology

    2012

    Non-significant trend toward extended botulinum toxin effect (3.7 months vs 3.0 months). One-third (4/12) of active group had significantly longer inter-injection interval (3.3-7.1 months vs standard 3 months). No severe adverse events.

  5. The study of cellular cytotoxicity of argireline - an anti-aging peptide

    In vitro cytotoxicity study3 cell lines (HEK-293, IMR-32, primary fibroblasts)N/A (in vitro)

    Grosicki M, Latacz G, Szopa A, Cukier A, Kiec-Kononowicz K

    Acta Biochimica Polonica

    2014

    Significant cytotoxicity of Argireline required 18- to 10,000-fold higher concentrations compared to doxorubicin, confirming low toxicity at cosmetic use concentrations.

  6. Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis

    Longitudinal analysis of public interest (Google Trends)N/A (Google Trends search data, January 1, 2013–January 1, 2023)10 years

    Olsson SE, Sreepad B, Lee T, Fasih M, Fijany A

    JMIR Dermatology

    2024

    Dramatic surge in public interest in Argireline in 2022, driven by TikTok popularization. Products under $100 OTC vs $300-600 for Botox. Safety was discussed using earlier literature; this Google Trends study did not test safety.

What research suggests over time

  • Weeks 2-4

    Topical RCT

    Early subjective reports of wrinkle smoothing.

  • Months 2-3

    Topical RCTs (mixed)

    Up to 30% wrinkle depth reduction at 30 days in early studies (Blanes-Mira 2002); 48.9% efficacy reported in a 2013 RCT.

  • Long-term

    Topical RCTs (mixed)

    More recent objective imaging study (2023) found NO statistically significant wrinkle reduction vs placebo. Effect size is real but inconsistent across trial methodologies.

Regulation & availability

Why researchers look at it

One RCT reported nearly 49% anti-wrinkle efficacy versus 0% for placebo, and a separate study showed up to 30% wrinkle depth reduction after 30 days — but a more rigorous 2023 study using objective Visia imaging found no statistically significant difference. Penetration studies show less than 0.2% of the peptide crosses the outer skin layer within 24 hours, explaining the gap between marketing claims and clinical results. If delivery technology advances to solve the penetration problem, the underlying Botox-like mechanism could prove far more effective than current formulations allow.

Estimated cost
$15-50/mo in OTC serums; $5-20 raw ingredient for DIY formulation
FDA status
Not FDA-approved as a drug. Argireline is used in cosmetic products; therapeutic claims trigger drug requirements. CIR's 2021 final assessment found acetyl hexapeptide-8 amide safe at actual peptide concentrations up to 0.005%, with insufficient safety data above that concentration. CIR assessment is not FDA approval. The INCI name is Acetyl Hexapeptide-8.
WADA status
Not specifically listed on the WADA Prohibited List. Argireline is a cosmetic peptide applied topically and is not classified among the prohibited peptide hormones, growth factors, or related substances under WADA Section S2. However, athletes should verify with their specific sporting federation before use, as WADA rules can be interpreted broadly for certain peptide categories.
Prescribability
No — Argireline is an over-the-counter cosmetic ingredient, not a prescription drug. It is regulated as a cosmetic by the FDA, not as a pharmaceutical.
Availability
Widely available over-the-counter globally. Argireline is incorporated into numerous cosmetic products including serums, creams, and eye treatments from brands ranging from The Ordinary to premium skincare lines. Typical product concentrations range from 0.001% to 10%, with most consumer serums containing 5-10% Argireline solution. Pure Argireline solution products typically cost under $100, compared to $300-600 for professional botulinum toxin injections. No prescription required.

International status

  • EU

    Available OTC in cosmetics (INCI listed)

  • US

    Available OTC in cosmetic products (not a drug)

  • Worldwide

    Regulated as cosmetic ingredient, not pharmaceutical

Regulatory timeline(9)

  1. 2000
    Argireline (acetyl hexapeptide-3/8) introduced commercially by Lipotec as a cosmetic peptide ingredient
  2. 2002
    First peer-reviewed study published (Blanes-Mira et al.) demonstrating mechanism of action and in vivo wrinkle reduction
  3. 2012
    Pilot RCT (Lungu et al.) for blepharospasm adjunct therapy published; Lubrizol acquires Lipotec
  4. 2013
    Randomized, placebo-controlled trial (Wang et al.) reports 48.9% anti-wrinkle efficacy in Chinese subjects
  5. 2014
    Cytotoxicity study (Grosicki et al.) confirms low cellular toxicity at cosmetic use concentrations
  6. 2021-04-05
    CIR releases its final assessment, concluding safety in reported cosmetic uses up to 0.005% actual peptide and insufficient safety data above that concentration.
  7. 2022
    Massive surge in public interest driven by TikTok and social media ("Botox in a bottle" trend)
  8. 2023
    Rigorous Visia imaging study (Henseler) finds no statistically significant wrinkle reduction attributable to Argireline specifically
  9. 2024
    JMIR Dermatology publishes longitudinal analysis of public interest in acetyl hexapeptide-8

Sources & FAQs

Research sources(5)

Frequently asked questions(5)

Is Argireline a replacement for Botox?

No. While Argireline targets the same SNARE complex pathway as botulinum toxin, its effects are far milder. Clinical evidence is mixed, with some studies showing wrinkle reduction and others finding no statistically significant effect. Less than 0.2% of topically applied Argireline penetrates the stratum corneum, limiting its ability to reach neuromuscular targets. It may serve as a complementary approach but is not considered an equivalent alternative to botulinum toxin injections.

What concentration of Argireline is most effective?

Clinical studies have primarily used 10% Argireline solution. The original 2002 study used a 10% concentration in an oil-in-water emulsion. Most consumer products contain 5-10% Argireline solution. Concentrations above 10% have not shown additional benefit in available studies.

How long does Argireline take to show results?

Studies suggest measurable changes may appear as early as 15 days of twice-daily application, with more significant results typically observed after 28-30 days of consistent use. Effects are temporary and require continued application.

Can Argireline be used with other skincare ingredients?

Yes. Argireline is often formulated with hyaluronic acid, other peptides (like matrixyl/palmitoyl pentapeptide), vitamin C, retinol, and niacinamide. No specific contraindications with other cosmetic ingredients have been identified. Multi-ingredient formulations may show more promise than single-ingredient applications.

Is Argireline safe during pregnancy?

No specific studies have evaluated Argireline use during pregnancy or breastfeeding. While there is no evidence of teratogenic effects, most dermatologists recommend consulting a physician before use during pregnancy as a precaution.